Onkologie. 2022:16(1):16-19 | DOI: 10.36290/xon.2022.003

The role of radiotherapy in renal cell carcinoma and the potential of its combination with immunotherapy

Milan Vošmik, Mustafa Aml Banni, Libor Hruška
Klinika onkologie a radioterapie, Lékařská fakulta Univerzity Karlovy v Hradci Králové a Fakultní nemocnice Hradec Králové

Immunotherapy has become a commonly used systemic treatment for advanced and metastatic renal cell carcinoma. The role of radiotherapy in renal cancer has shifted from palliative irradiation to the stereotactic, cranial and extracranial, radiotherapy and radiosurgery, which can be an effective alternative to surgery, especially in oligometastatic disease. The hypothesis that radiotherapy can activate the immune system and thus increase the effectiveness of immunological treatment seems promising. Unfortunately, there is still very little clinical data on the true efficacy of the combination of radiotherapy and immunotherapy for renal cell carcinoma. The true clinical benefit can only be confirmed by the results of randomized clinical trials.

Keywords: radiotherapy, stereotactic radiotherapy, immunotherapy, renal cell carcinoma.

Published: February 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vošmik M, Banni MA, Hruška L. The role of radiotherapy in renal cell carcinoma and the potential of its combination with immunotherapy. Onkologie. 2022;16(1):16-19. doi: 10.36290/xon.2022.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2021-9-25]. Dostupný z: http://www.svod.cz. Verze 7.0 [2007].
    2. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 1996;34(1):251-266. Go to original source... Go to PubMed...
    3. Juusela H, Malmio K, Alfthan O, et al. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol. 1977;11(3):277-281. Go to original source... Go to PubMed...
    4. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. 1987;13(5):665-672. Go to original source... Go to PubMed...
    5. Staehler M, Bader M, Schlenker B, et al. Single fraction radiosurgery for the treatment of renal tumors. J Urol. 2015;193(3):771-775. Go to original source... Go to PubMed...
    6. Siva S, Pham D, Gill S, et al. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 2012;110(11 Pt B):E737-743. Go to original source... Go to PubMed...
    7. Yamamoto T, Kadoya N, Takeda K, et al. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma. Radiat Oncol. 2016;11:72. Go to original source... Go to PubMed...
    8. Hilleary LA, Wratten C, Siva S, et al. Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report. BMC Cancer. 2019;19(1):671. Go to original source... Go to PubMed...
    9. Ikushima H, Tokuuye K, Sumi M, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2000;48(5):1389-1393. Go to original source... Go to PubMed...
    10. Noel G, Valery CA, Boisserie G, et al. LINAC radiosurgery for brain metastasis of renal cell carcinoma. Urol Oncol. 2004;22(1):25-31. Go to original source... Go to PubMed...
    11. Scorsetti M, Facoetti A, Navarria P, et al. Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases. Anticancer Res. 2009;29(10):4259-4263. Go to PubMed...
    12. Wersäll PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77(1):88-95. Go to original source... Go to PubMed...
    13. Hoerner-Rieber J, Duma M, Blanck O, et al. Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group "Stereotactic Radiotherapy". J Thorac Dis. 2017;9(11):4512-4522. Go to original source... Go to PubMed...
    14. Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015;54(2):148-157. Go to original source... Go to PubMed...
    15. Zaorsky NG, Lehrer EJ, Kothari G, et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019;2(5):515-523. Go to original source... Go to PubMed...
    16. Wersäll PJ, Blomgren H, Pisa P, et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006;45(4):493-497. Go to original source... Go to PubMed...
    17. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-931. Go to original source... Go to PubMed...
    18. Hori K, Hirohashi Y, Aoyagi T, et al. Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report. Exp Ther Med. 2020;19(3):1903-1907. Go to original source... Go to PubMed...
    19. Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 2001;93:539-548. Go to original source... Go to PubMed...
    20. Vošmik M. Mechanismus synergie radioterapie a terapie pomocí checkpoint inhibitorů, Onkol Revue. 2020;7(1 Spec.):11-15.
    21. Pohanková D, Kopecký J. Kombinovaná léčba radioterapie s checkpoint inhibitory. Onkologie. 2020;14(5):213-218. Go to original source...
    22. Flippot R, Dalban C, Laguerre B, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol. 2019;37(23):2008-2016. Go to original source... Go to PubMed...
    23. Chen L, Douglass J, Kleinberg L, et al. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(4):916-925. Go to original source... Go to PubMed...
    24. Masini C, Iotti C, De Giorgi U, et al. Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study. Journal of Clinical Oncology. 2020;38(6_suppl):613-613. Go to original source...
    25. Hammers HJ, Vonmerveldt D, Ahn C, et al. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). Journal of Clinical Oncology. 2020;38(6_suppl):614-614. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.